Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash & Equivalents (2016 - 2025)

Regenxbio has reported Cash & Equivalents over the past 12 years, most recently at $34.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $34.5 million for Q4 2025, down 40.09% from a year ago — trailing twelve months through Dec 2025 was $34.5 million (down 40.09% YoY), and the annual figure for FY2025 was $34.5 million, down 40.09%.
  • Cash & Equivalents for Q4 2025 was $34.5 million at Regenxbio, down from $58.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RGNX hit a ceiling of $345.2 million in Q4 2021 and a floor of $34.5 million in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $88.3 million (2022), compared with a mean of $123.2 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 319.94% in 2021 and later plummeted 71.91% in 2022.
  • Regenxbio's Cash & Equivalents stood at $345.2 million in 2021, then plummeted by 71.91% to $97.0 million in 2022, then tumbled by 64.39% to $34.5 million in 2023, then skyrocketed by 66.64% to $57.5 million in 2024, then crashed by 40.09% to $34.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $34.5 million (Q4 2025), $58.8 million (Q3 2025), and $79.6 million (Q2 2025) per Business Quant data.